Tiziana Reduction in Microglia Activation in PET Scan in Alzheimer's Treated Intranasally

Tiziana Life Sciences (NASDAQ: TLSA) reported promising results from a PET scan showing significant reduction in microglia activation in a moderate Alzheimer's disease patient treated with intranasal foralumab for three months under an expanded access program. The scan revealed decreased neuroinflammation, a key factor in Alzheimer's progression. Dr. Howard Weiner presented these findings at the 2025 AD/PD Conference in Vienna. The treatment showed no side effects, and the patient continues receiving foralumab. This breakthrough is particularly significant as no approved therapies currently exist for moderate Alzheimer's. Foralumab, a fully human anti-CD3 monoclonal antibody, works by inducing Tregs that travel to the brain to reduce neuroinflammation. The treatment shows potential both as a standalone therapy and in combination with existing amyloid-targeting treatments.

https://www.stocktitan.net/news/TLSA/tiziana-life-sciences-announces-significant-reduction-in-microglia-aixxscmgfywp.html